Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

69.43EUR
29 Aug 2016
Change (% chg)

€0.08 (+0.12%)
Prev Close
€69.35
Open
€69.53
Day's High
€69.67
Day's Low
€68.73
Volume
1,222,127
Avg. Vol
2,448,683
52-wk High
€93.82
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production... (more)

Overall

Beta: 0.79
Market Cap(Mil.): €89,392.88
Shares Outstanding(Mil.): 1,289.01
Dividend: 2.93
Yield (%): 4.22

Financials

  SASY.PA Industry Sector
P/E (TTM): 21.84 36.93 36.63
EPS (TTM): 3.18 -- --
ROI: 4.96 14.69 14.12
ROE: 7.50 15.48 15.04

BRIEF-Sanofi and Regeneron say Praluent shows positive phase 3 trial data

* Sanofi and Regeneron say Praluent shows positive investigational data in phase 3 trial Further company coverage: (Reporting by Laurence Frost)

29 Aug 2016

Pfizer's Medivation buy seen prescribing more biotech M&A

Medivation's $14 billion sale to U.S. drug giant Pfizer Inc for a hefty premium, the largest U.S. biotechnology acquisition so far this year, had investors on Monday speculating about more dealmaking in the sector.

22 Aug 2016

Pfizer's Medivation buy seen prescribing more biotech M&A

Aug 22 Medivation's $14 billion sale to U.S. drug giant Pfizer Inc for a hefty premium, the largest U.S. biotechnology acquisition so far this year, had investors on Monday speculating about more dealmaking in the sector.

22 Aug 2016

Sanofi says talked with Medivation, but will be "disciplined" acquirer

PARIS, Aug 22 French pharmaceutical group Sanofi reacted to Pfizer's roughly $14 billion cash deal for Medivation Inc by saying it had appreciated the chance to engage in talks with Medivation in past weeks.

22 Aug 2016

Thousands of women took Sanofi epilepsy drug despite risk to fetuses - media

PARIS More than 10,000 pregnant women in France took Sanofi's anti-epilepsy drug Depakine between 2007 and 2014 although the risk of fetus malformation was known, according to a study quoted by French satirical weekly Le Canard Enchaine.

09 Aug 2016

Thousands of women took Sanofi epilepsy drug despite risk to fetuses: media

PARIS More than 10,000 pregnant women in France took Sanofi's anti-epilepsy drug Depakine between 2007 and 2014 although the risk of fetus malformation was known, according to a study quoted by French satirical weekly Le Canard Enchaine.

09 Aug 2016

Thousands of women took Sanofi epilepsy drug despite risk to fetuses-media

PARIS, Aug 9 More than 10,000 pregnant women in France took Sanofi's anti-epilepsy drug Depakine between 2007 and 2014 although the risk of fetus malformation was known, according to a study quoted by French satirical weekly Le Canard Enchaine.

09 Aug 2016

Regeneron sticks by 2016 growth forecast for Eylea, shares fall

Regeneron Pharmaceuticals Inc stood by its full-year growth forecast for flagship eye drug Eylea as the company posted its slowest growth in revenue in eight quarters.

04 Aug 2016

REFILE-UPDATE 3-Regeneron sticks by 2016 growth forecast for Eylea, shares fall

Aug 4 Regeneron Pharmaceuticals Inc stood by its full-year growth forecast for flagship eye drug Eylea as the company posted its slowest growth in revenue in eight quarters.

04 Aug 2016

Sanofi gains EU approval for Boehringer consumer health unit buy

BRUSSELS French drugmaker Sanofi secured EU antitrust approval on Thursday for its proposed buy of German peer Boehringer Ingelheim's consumer health business after agreeing to divest businesses from both companies in nine EU countries.

04 Aug 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
£10.00
Provider : Reuters Investment Profile
£10.00
Provider : Ford Investor Services, Inc.
£8.00
Provider : S&P Capital IQ – STARS Reports
£82.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.